Literature DB >> 120407

Variations in surface protein composition associated with virulence properties in opacity types of Neisseria gonorrhoeae.

P R Lambden, J E Heckels, L T James, P J Watt.   

Abstract

The biological properties of a series of opacity variants of Neisseria gonorrhoeae P9 have been examined. A novel protein, designated protein IId* (mol. wt 28 850), was identified within the set of heat-modifiable surface proteins previously reported. All variants producing extra outer membrane proteins were less sensitive to the bactericidal action of serum than the prototype transparent strain, with protein IIa* (mol. wt 28 500) being associated with increased resistance. The production of a different protein, protein II* (mol. wt 29 000), was correlated with resistance to low molecular weight antimicrobial agents (penicillin, fusidic acid, Cu2+, Zn2+). Increased adhesion to human buccal epithelial cells was demonstrated in all variants that produced extra surface proteins. These variants did not show increased binding to hexyl- and phenyl-substituted Sepharose gels suggesting that hydrophobic interaction was not responsible for their cohesive properties. The prototype strain lacking additional proteins demonstrated the greatest binding to erythrocytes, indicating that adhesion to buccal cells and red blood cells is mediated by different mechanisms. One variant producing protein IIa* showed increased association with leukocytes, whereas another producing protein IIb* showed decreased association with leukocytes. These results show that the heat-modifiable surface proteins are important virulence attributes of the gonococcus: this must be considered in the selection of strains for vaccine trials.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 120407     DOI: 10.1099/00221287-114-2-305

Source DB:  PubMed          Journal:  J Gen Microbiol        ISSN: 0022-1287


  82 in total

1.  Relation of capsular polysaccharide production and colonial cell organization to colony morphology in Vibrio parahaemolyticus.

Authors:  J L Enos-Berlage; L L McCarter
Journal:  J Bacteriol       Date:  2000-10       Impact factor: 3.490

Review 2.  Genetic mechanisms and biological implications of phase variation in pathogenic neisseriae.

Authors:  T F Meyer; J P van Putten
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

Review 3.  Gonococcal vaccines.

Authors:  E C Tramont
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

4.  Anaerobic growth of gonococci does not alter their Opa-mediated interactions with human neutrophils.

Authors:  J V Frangipane; R F Rest
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

5.  Antigenicity of fractions of Helicobacter pylori prepared by fast protein liquid chromatography and urease captured by monoclonal antibodies.

Authors:  A R Stacey; P R Hawtin; D G Newell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

6.  Conservation of peptide structure of outer membrane protein-macromolecular complex from Neisseria gonorrhoeae.

Authors:  M V Hansen; C E Wilde
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

7.  Effect of anti-pilus antibodies on survival of gonococci within guinea pig subcutaneous chambers.

Authors:  P R Lambden; J E Heckels; P J Watt
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

8.  Growth of Neisseria gonorrhoeae in CMP-N-acetylneuraminic acid inhibits nonopsonic (opacity-associated outer membrane protein-mediated) interactions with human neutrophils.

Authors:  R F Rest; J V Frangipane
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

9.  The virulence of clinical and environmental isolates of Campylobacter jejuni.

Authors:  D G Newell; H McBride; F Saunders; Y Dehele; A D Pearson
Journal:  J Hyg (Lond)       Date:  1985-02

10.  OpaR, a homolog of Vibrio harveyi LuxR, controls opacity of Vibrio parahaemolyticus.

Authors:  L L McCarter
Journal:  J Bacteriol       Date:  1998-06       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.